ArticleiLIVER2023

Evaluating Tislelizumab, Lenvatinib, and FOLFOX4-HAIC as a Conversion Therapy for Unresectable Hepatocellular Carcinoma.

Kai Tan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.